Sartorius Stedim Biotech Shares Slide to €159.10, Remain Under Technical Pressure
The biopharmaceutical equipment specialist drops 2.45% at midday to €159.10. The stock is trading below its three main moving averages and has fallen 21.39% over the past twelve months. In a CAC 40 down by 1.42%, the stock ranks in the lower half of the SBF 120.
The Stock Breaks Through Its Moving Averages
Sartorius Stedim Biotech shares are below their 20-day moving average (MM20) of €166.85 by 4.64%, and even more so below their 200-day moving average (MM200) at €185.51 (a gap of 14.24%). This setup extends the underlying trend that began after the first quarter results on April 23, where the near-stagnation of the EBITDA margin weighed on the stock. The price is in the lower part of the Bollinger Bands (34%), with a lower boundary at €142.89. The RSI at 47 remains neutral, not confirming an oversold signal despite the day's downward movement. The technical support identified at €151.50 serves as the next downward reference, while the resistance of €188.70 remains distant.
Tight Valuation Compared to the Health Care Sector Average
Based on the expected earnings per share, the stock is trading at about 31.5 times the 2026 earnings and 26.3 times those of 2027, according to the consensus of ten analysts updated on May 12, 2026. This level remains significantly above the current year's Health Care sector average of 18.8 times earnings. The expected year-over-year EPS growth reaches 20%. The market is also moving in a context of nervousness with Brent crude exceeding $109 and a notably declining CAC 40. The next significant event for the stock is the publication of the 2026 half-year results, expected on July 23, 2026.
